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Prothymosin-a (ProTa) and thymosin-8, (TB,) were isolated from murine thymus and characterized by microsequence analysis. Murine TB, has 
an identical sequence to bovine TB,, whereas murine ProTa is highly homologous to rat ProTa. Murine ProTa differs from rat ProTa at two posi- 
tions, Glory and Aspro* of the rat sequence are substituted by aspartic and ghttamic acid, respectively, in murine ProTa. The amount of ProTa 
in murine thymus was found to be reduced after in vivo treatment with staphylococcal enterotoxin-B (SEB), a superantigen which stimulates T 
cells bearing specific V, receptors. Results from the anti-SRBC (sheep erythrocyte) plaque-forming cell assay showed that the antibody response 
of the spleen cells from these animals was also suppressed. On the other hand, the amount of TB, was not changed significantly. Our studies suggest 
that the suppression of SEB on antibody response correlates with the depression of ProTa production in the thymus. 
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1. INTRODUCTION 
Thymic hormones play an important role in pro- 
moting the maturation and differentiation of lymphoid 
precursor cells into immunocompetent T cells [ 11. Two 
of the thymic hormones, prothymosin-a (ProTa) and 
thymosin-04 (T&), have been isolated from various 
animal and tissue sources [2-51. ProTa contains 
thymosin-ar [6] sequence at its amino terminus. 
Biologically, ProTa enhances resistance to oppor- 
tunistic infections [7] and restores mixed lymphocyte 
responses [8]. T& induces terminal deoxynucleotidyl 
transferase (TdT) in vivo and in vitro [9] and stimulates 
release of leuteinizing hormone [lo]. 
To identify murine ProTa and Tfl4, they were first 
isolated from normal murine thymus and characterized 
by microsequence analysis. Thymic extracts from SEB- 
treated groups were prepared and fractionated by 
reversed phase high-performance liquid chromato- 
graphy (HPLC). Peaks corresponding to murine ProTa 
and To4 were collected and quantitated by amino acid 
analyses. In addition, the plaque-forming cell responses 
of the spleen cells were studied. Our results suggest hat 
immunosuppression induced by SEB injection cor- 
relates with the thymic hormone modulation. 
Staphylococcal enterotoxin-B (SEB), a superantigen 
which stimulates T cells bearing specific VB receptors, 
has been shown to induce suppressor cell populations 
which inhibit both humoral and cell-mediated immune 
responses [ 1 l-151. However, the mechanism of such 
immunosuppression is not clear. In order to evaluate 
the role of thymic hormones in SEB-induced im- 
munosuppression, we have determined the concentra- 
tion of ProTa and T/34 in murine thymus after in vivo 
treatment of SEB. 
2. MATERIALS AND METHODS 
2.1. Materials 
Trifluoroacetic acid (TFA) and fluorescamine (Fluram) were ob- 
tained from Pierce. Trypsin-TPCK was purchased from Cooper 
Biomedical. Acetonitrile was a product of Merck (Frankfurt, FRG). 
All other chemicals were of reagent grade and were used without fur- 
ther purification. 
2.2. Isolation and characterization of murine ProTcr and Tf14 
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Murine thymic tissues were excised from young BALB/c mice (4-6 
weeks of age). Tissue extract was prepared as described previously [2]. 
Fresh tissues were cut into pieces and boiled for 5 min in water. The 
chilled suspension was homogenized with polytron (Brinkman) and 
centrifuged at 16 000 x g for 30 min. The supernatant was filtered, 
titrated to pH 3 and again centrifuged. The lyophilized crude extract 
(30 mg by Lowry method 1161) was chromatographed on Sephadex 
G-100 (1.6 x 100 cm) in 0.01 M ammonium bicarbonate, pH 8.0. 
Peptides in each protein pool were purified by HPLC (Waters Ass.) 
using a reverse phase column @Bondapak Crs column, 30 x 0.39 
cm). Solvent A contained 0.05% TFA and solvent B contained 
acetonitrile with 0.05% TFA. A linear gradient of lo-25Vo B in 60 
min was used. Amino acid analysis was carried out using a Beckman 
6300 analyzer. Digestion of purified peptides with trypsin was per- 
formed in 1% ammonium bicarbonate at pH 8.0 for 2.5 h at 37°C. 
Published by Elsevier Science Publishers B. V. (Biomedical Division) 
00145793/90/$3.50 0 1990 Federation of European Biochemical Societies 1 
Vdume 273, number 1,2 FBBS LBTTERS October 1990 
Cyanogen bromide cleavage was performed in 70% formic acid. The 
rryptic digests or cyanogen bromide fragments were fractionated by 
HFLC. Peptides which were poorly resolved by FIFLC were purified 
by high vohage paper electrophoresis at pH 1.9 (Savant, Farm- 
ingdale, NY). Sequence analysis was carried out using a gas-phase se- 
quencer (Applied Biosystems, Model 477A) with an on-line PTH 
analyzer (Model 12OA). 
2.3. In vivo treatment with SEB or saline 
BALB/c mice, 6-8 weeks of age, were obtained from National 
Cheng Kung University Animal Center. Mice (4 per group) were in- 
jected intravenously with 0.2 ml SEB (Sigma, St. Louis, MO, IO0 
pg/ml in saline) per animal, Each mouse in the controi groups receiv- 
ed 0.2 ml saline. They were sacrificed 4 h, 1 day, 2 days, 3 days, 4 days 
or 7 days post SEB injection. In addition, 5 days prior to sacrificing, 
each animal was also primed with 0.5 mZ of 0. t C sheep erythrocytes 
(SRBC) intraperitonc~1~. 
2.4. Isolation and quuntitation ofProTcv and Tad in 333~ or saline- 
treated mice 
Thymus glands were removed immediately from the sacrificed 
mice. Tissues from each experimental group were pooled and weigh- 
ed. They were extracted as described above. The crude extra& were 
fractionated by HPLC. Peaks which corresponded to murine ProTo 
and T/34 were collected, lyophilized and analyzed. The amount con- 
tained in each peak was estimated by amino acid analysis. 
The anti-SRBC plaque-forming cep (PFC) response was determin- 
ed by the ~unningh~ slide rn~Bc~~n of the Jere hemolytic pla- 
que assay [l?]. Single cell suspensions were prepared from immunized 
mouse spleens. Triplicate determinations of the PFC response were 
performed for each group. Only the direct (JgM) PFC responses were 
measured. Results are expressed as PFC/lO* cells. 
3. RESULTS AND DISCUSSION 
Murine ProTcl, and T,& were isolated from pooled 
thymic tissues by beating, homogenization, centrifuga- 
tion, gel-filtration and HPLC on reverse phase Cts col- 
umn. The yield of purified T& was 50 pg/g wet thymic 
tissue and 95 pug/8 for purified ProTa, The primary 
structures of murine T@4 and Profrp were determined 
by sequence analyses of purified tryptic peptides and 
cyanogen bromide fragments. As shown in Fig. 1, the 
amino acid sequence of murine T,& is identical to 
bovine or porcine Tfl4 [2,5]. The primary structure of 
murine ProTtr was determined except for a segment 
consisting of residues 53-89. It contains the thymosin- 
CK~ at its amino terminus. Murine ProTcv differs from 
rat ProTcv 1181 at two positions, GIu’~ and Asp”* of 
the rat sequence are substitute by aspartic acid and 
glutamic acid, respectively, in murine ProTcu. 
We next investigated the effects of SEB treatment on 
the thymic hormone production in the thymus, Thymic 
extracts were prepared from each experimental group 
and fractionated by HPLC. Characterization of peaks 
1 and 2 in Fig. 2 as T& and ProTa, respectively, has 
been accomplished by: (i) amino acid compositional 
analyses; and (ii) comparison of retention time in 
HPLC elution profiles with those of purified murine 
T& and ProTcr, Figs. 2A-D show the HPLC elution 
profiles of crude thymic extracts prepared from mice 
2 
which were sacrificed 4 h, 2 days, 3 days or 7 days post 
SEB injection. Figs. 2E-H are the profiles from saline- 
treated groups. Table I lists the quantitative results 
calculated from amino acid analyses. The concentration 
of ProTcv in the thymus was reduced two days post SEB 
injection. The lowest value was reached at 3 days. The 
changes were not as obvious for Tfi4 with only slight in- 
creases at 1 day to 3 days post SEB injection. Finally, 
we studied the effect of in vivo SEB treatment on the 
immune response in the spleen using an anti-SRBC 
plaque-fo~ng cell (PFC) assay. Our results, as shown 
in Table II, showed that the anti-SRBC PFC response 
was suppressed when SEB was given to mice for 2 days, 
but not for 1 day or 4 h. The suppressive activity induc- 
ed by SEB sustained up to 7 days. Taken together, our 
data suggest hat there is a good correlation between the 
depression of ProTa! production in the thymus and the 
suppression of antibody response in the spleen which 
was mediated by SEB treatment. 
It has been demonstrated that suppressor cell popula- 
tions, capable of suppressing both humoral and cell- 
mediated immune responses, are activated by SEB 
fi I-IS], Furthermore, the SEB-induced mitogenesis re- 
quires the participation of both Ia and the T-cell an- 
tigenic receptor complex [19-211. The a~~vation of sup- 
pressor cells with SEB appears to occur through the in- 
duction of the T-cell subpopulation expressing the 
Ly-1+,2-, Ly-l-,2’ or Ly-1+,2+ cell surface 
phenotypes. However, the mechanism of such im- 
munosuppression is not clear. Most recently, Marrack 
et al. 1221 provided evidence that the toxicity of SEB in 
mice is mediated by T cells. They also suggested that the 
SEB-activated T cells secrete different lymphokines 
which in turn exert toxic effects, Our studies suggest 
that such ~~osuppression or toxic effects might in- 
volve the mutation of ProTrr and other thymic hor- 
mones in the thymus. 
By Northern blot analysis, ProTcv mRNA was found 
to be most abundant in the thymus 1231. However, the 
ProTa gene is also expressed in many other tissues in- 
cluding ovary, kidney, brain, heart, intestine, lung and 
spleen, suggesting a general role for this protein. In 
thymus, ProTa! gene expression changes during the 
maturation of T-lymphocytes, increasing from pm-T 
cells to immature thymocytes and decreasing in mature 
thymocytes, spleen Ig - l~pho~~es and circulating 
lympho~~~_ Thus, the change in ProTm concentration 
in the thymus upon SE3 ~imula~on might represent a 
process of T-cell activation and differentiation which 
resulted a redistribution of T-cell populations. Further- 
more, it has been reported that several-fold increase of 
ProTa mRNA was induced upon in vitro treatment of 
human peripheral blood lymphocytes with staphylococ- 
cal enterotoxin A (SEA) [24]. The differential effect ex- 
erted by these enterotoxins on the thymus and 
peripheral blood lymphocytes suggests the existence of 
different mechanisms due to variations in cell popula- 
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Fig. 1. The amino acid sequence of murine prothymosin-tu (ProTo) and thymosin-,& (T,%). Peptides generated by treatment with try@, ther- 
molysin and cyanogen bromide are designated T, Th and CN, respectively. Sequences established by automated sequence analysis are shown by 
solid lines. Unsequenced portions are shown by dashed lines. The N-terminal ends of both ProTa and T@.+ were blocked and were not identified. 
The tryptic peptides of murine ProTa are placed by homology with the sequence of rat ProTtv fl$]. Residues differing between the two ProTo 
mole&es are boxed. 
20 40 
TIME (minutes) 
Fig. 2. Effect of in vivo SEB treatment on ProTp production in murine thymus. (A) Mice were sacrificed 4 h post-SEB injection. Crude thymic 
extract was prepared and fractionated by HPLC. Peaks 1 and 2 were identified as T@.+ and ProTcu, respectively. The peaks were collected and quart- 
titated by amino acid aualysis. (B-D) HPLC profiles of thymic extracts from mice which were sacrificed 2 days, 3 days and 7 days post SEB injec- 
tion. (E-H) HPLC profiles of thymic extracts from saline-treated groups. Mice were sacrificed 4 h, 2 days, 3 days and 7 days post saline treatment. 
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Table I 
Concentration of ProTcv in murine thymus after in vivo treatment with SEB 
Days after 
treatment8 SEB 
ProTab TAb 
Saline % Decrease SEB Saline 
Exp. I 
l/6 
1 
2 
3 
4 
7 
140 137 -2 62 54 
118 123 4 62 51 
68 126 46 60 57 
56 137 59 63 56 
10.5 113 7 55 55 
113 118 4 46 48 
Exp. 2 
l/6 130 126 -3 42 43 
1 106 113 6 58 41 
2 52 120 57 50 45 
3 46 127 64 57 44 
4 85 99 14 41 45 
7 95 109 13 36 34 
“Amounts expressed as ,ug/g thymus tissue, based on amino acid analysis result of HPLC separated peptides. 
Mice without saline treatment contained 130 pg of ProTcv and 55 pg of T& per gram of thymus tissue. Results 
from two experiments are shown. bBALB/c mice were treated with 2O/cg SEB in 0.2 ml or with 0.2 ml saline i.v. 
on various days 
Table II 
Effect of in vivo SEB treatment on anti-SRBC plaque-forming cell 
resnonse 
Days after 
treatmenta 
PFC/lO* cells ( f SD)b 
SEB 
l/6 33 06Ozt 1850 
1 22 300f 730 
2 370* 170 
3 3 9lOf 1160 
4 2 250* 350 
7 1 8602 1790 
Saline Vo Decrease 
40 530~1~ 730 18 
23 06Ort2180 3 
30 45Oztz2320 99 
44 56Ort3680 91 
28 83Oi2500 92 
5044Ozt2500 92 
‘BALB/c mice were treated with 2OFg SEB in 0.2 ml or with 0.2 ml 
saline i.v. on various days 
bMice were immunized with 0.5 ml of 0.1070 SRBC i.p. and the anti- 
SRBC plaque-forming cell (PFC) responses were determined after 5 
days. The PFC response for positive control (without saline or SEB 
treatment) was 35 900& 1350/10* splenocytes, and the negative con- 
trol was SO* 50/10* splenocytes. Average from a group of 5 mice in 
a representative experiment is shown ( ZIZ SD) 
tions. It was found that the depression of ProTcv ap- 
peared on days 2 and 3 after SEB treatment and return- 
ed to normal on day 4, whereas the anti-SRBC plaque- 
forming cell response was sustained for a longer period 
of time. The possible explanations for these observa- 
tions include: (i) these two events may occur via dif- 
ferent mechanisms; (ii) the anti-SRBC response may be 
the secondary effect which lasts longer due to the induc- 
tion of suppressor cells or other specific suppressions. 
Further studies are needed to reveal the significance of 
the correlation between ProTLv and the immune 
response mediated by SEB. 
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